ACTIVATION OF TUMOR-REACTIVE LYMPHOCYTES VIA ANTIBODIES OR GENES RECOGNIZING CD3 OR 4-1BB

摘要

An improved method for ex-vivo generation of tumor-reactive T cells is provided, comprising, for example, culturing PBMC from a patient with cancer with autologous tumor cells and magnetic beads that can activate T lymphocytes via CD3 in combination with CD28, CD40, or CD28 plus CD40. The invention also provides genes encoding anti-CD3 or anti-4­1BB scFv and methods to transfect cells of neoplastic or normal origin for expression of those genes at their surface. The genes and transfected tumor cells are useful compositions for induction of a tumor-destructive immune response.